Nucleic acids coding for antibodies against human IL-21 receptor and uses therefor
US8143385B2 · kind B2 · utility
6Cited by
23References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 14, 2009 |
| Grant date | Mar 27, 2012 |
| Priority date | — |
| Expiry date | Sep 18, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/622
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.